| Primary | Baseline Pre-bronchodilator FEV1 (L) | Forced expiratory volume in 1 second (FEV1) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic. | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Mean | Standard Deviation | L | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG0001.49± 0.539
- OG0011.44± 0.519
|
|
| |
| Primary | End-value Pre-bronchodilator FEV1 (L) | End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF) | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Least Squares Mean | Standard Error | L | | up to week 12 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Post-bronchodilator FEV1 (L) - Baseline | Forced expiratory volume in 1 second (FEV1) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic. | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Mean | Standard Deviation | L | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Post-bronchodilator FEV1 (L) - End-value | End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF) | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Least Squares Mean | Standard Error | L | | up to week 12 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Pre-bronchodilator FVC (L) - Baseline | Forced vital capacity (FVC) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic. | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Mean | Standard Deviation | L | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Pre-bronchodilator FVC (L) - End-value | End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF) | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Least Squares Mean | Standard Error | L | | up to week 12 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Post-bronchodilator FVC (L) - Baseline | Forced vital capacity (FVC) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic. | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Mean | Standard Deviation | L | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Post-bronchodilator FVC (L) - End-value | End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF) | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Least Squares Mean | Standard Error | L | | up to week 12 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Baseline Pre-bronchodilator FEV6 (L) | Forced expiratory volume in 6 seconds (FEV6) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic. | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Mean | Standard Deviation | L | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | End-value Pre-bronchodilator FEV6 (L) | End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF) | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Least Squares Mean | Standard Error | L | | up to week 12 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Baseline Post-bronchodilator FEV6 (L) | Forced expiratory volume in 6 seconds (FEV6) as a measure of lung function, measured post after bronchodilator (salbutamol) use in the clinic. | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Mean | Standard Deviation | L | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | End-value Post-bronchodilator FEV6 (L) | End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF) | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Least Squares Mean | Standard Error | L | | up to week 12 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Baseline Pre-bronchodilator FEF25-75% (L/Sec) | Forced expiratory flow between 25% to 75% of vital capacity (FEF25-75%) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic. | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Mean | Standard Deviation | L/sec | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | End-value Pre-bronchodilator FEF25-75% (L/Sec) | End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF) | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Least Squares Mean | Standard Error | L/sec | | up to week 12 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Baseline Post-bronchodilator FEF25-75% (L/Sec) | Forced expiratory flow between 25% to 75% of vital capacity (FEF25-75%) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic. | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Mean | Standard Deviation | L/sec | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | End-value Post-bronchodilator FEF25-75% (L/Sec) | End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF) | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Least Squares Mean | Standard Error | L/sec | | up to week 12 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Pre-bronchodilator IC (L) - Baseline | Inspiratory capacity (IC) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic. | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Mean | Standard Deviation | L | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Pre-bronchodilator IC (L) - End-value | End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF) | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Least Squares Mean | Standard Error | L | | up to week 12 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Post-bronchodilator IC (L) - Baseline | Inspiratory capacity (IC) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic. | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Mean | Standard Deviation | L | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Post-bronchodilator IC (L) - End-value | End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF) | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Least Squares Mean | Standard Error | L | | up to week 12 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | PEF - Baseline Measured by Patient at Home (L/Min) in the Morning | Peak Expiratory Flow (L/min) as a measure of lung function, measured at home by the patient each morning. Baseline is the mean of last 10 days of data before start of treatment. | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Mean | Standard Deviation | L/min | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | PEF - End-value Measured by Patient at Home (L/Min) in the Morning | Peak expiratory flow (PEF) | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Least Squares Mean | Standard Error | L/min | | Last 6 weeks on treatment | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | FEV1 - Baseline Measured by Patient at Home (L) in the Morning | Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured at home by the patient each morning. Baseline is the mean of last 10 days of data before start of treatment. | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Mean | Standard Deviation | L | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | FEV1 - End-value Measured by Patient at Home (L) in the Morning | Forced Expiratory Volume in 1 second (L) | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Least Squares Mean | Standard Error | L | | Last 6 weeks on treatment | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | EXACT - Baseline Total Score | EXAcerbations of Chronic pulmonary disease Tool, patient questionnaire as a measure of respiratory symptoms (reported as units on a 0 (best health status) to 100 (worst possible status) scale). Baseline is the mean of last 10 days of data before start of treatment. | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | EXACT - End-value Total Score | EXAcerbations of Chronic pulmonary disease Tool, patient questionnaire as a measure of respiratory symptoms (reported as units on a 0 (best health status) to 100 (worst possible status) scale). | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Least Squares Mean | Standard Error | units on a scale | | Last 6 weeks on treatment | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | BCSS - Baseline Total Score | Breathlessness, Cough and Sputum Scale, patient reported questionnaire as a measure of respiratory symptoms (reported on a 0 (best health status) to 12 (worst possible status) scale). Baseline is the mean of last 10 days of data before start of treatment. | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | BCSS - End-value Total Score | Breathlessness, Cough and Sputum Scale, patient reported questionnaire as a measure of respiratory symptoms (reported on a 0 (best health status) to 12 (worst possible status) scale). | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Least Squares Mean | Standard Error | units on a scale | | Last 6 weeks on treatment | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Sputum Colour - Baseline | Sputum Colour as assessed by the Bronkotest scale, reported on a scale from 1 - clear (best health status) to 5 - dark green (worst possible health status). | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Sputum Colour - End Value | Sputum Colour as assessed by the Bronkotest scale, reported on a scale from 1 - clear (best health status) to 5 - dark green (worst possible health status). End of treatment week 12 | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Least Squares Mean | Standard Error | units on a scale | | End of treatment week 12 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Use of Reliever Medication | Daily average of number of inhalations of reliever medication | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Least Squares Mean | Standard Error | inhalations | | Last 6 weeks on treatment | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Incremental Shuttle Walk Test - Baseline | | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Mean | Standard Deviation | seconds | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Incremental Shuttle Walk Test - End Value | | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Least Squares Mean | Standard Error | seconds | | Week 12 - visit 6 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Endurance Shuttle Walk Test - Baseline | | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Mean | Standard Deviation | seconds | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Endurance Shuttle Walk Test - End Value | Assessed at vist 6 -( last on treatment clinic visit) | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Least Squares Mean | Standard Error | seconds | | Week 12 - visit 6 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | St George's Respiratory Questionnaire (COPD) - Overall Score at Baseline | St George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease, as a measure of Quality of Life (reported on a scale from 0 (best health status) to 100(worst possible status)). | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Mean | Standard Deviation | Scores on a scale | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | St George's Respiratory Questionnaire (COPD) - End-value Overall Score | St George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease, as a measure of Quality of Life (reported on a scale from 0 (best health status) to 100(worst possible status)).Questionaire assessed on vist 6 -( last on treatment clinic visit) | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Least Squares Mean | Standard Error | Scores on a scale | | Measured Day 1 and 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |
| Secondary | Exacerbations - Clinic Defined | Number of patients having a clinic defined disease exacerbation. | The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle. | Posted | | Number | | Participants | | Duration of the the treatment period - 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | 60 mg AZD9668 | AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks | | OG001 | Placebo | |
| |